BioCentury | Apr 1, 2013
Clinical News

Endometrial Regenerative Cells: Preliminary Phase II data

...the Journal of Translational Medicine. ERCell has exclusive rights to ERCs from Medistem in Russia. ERCell LLC...
BioCentury | Jul 23, 2012
Clinical News

Endometrial Regenerative Cells: Phase I/II started

...50 million, 100 million and 200 million intramuscular ERC in about 15 patients with CLI. ERCell...
...Chinese market. Medistem and Jia Fu are initially focusing on CLI (see BioCentury, Feb. 27). ERCell LLC...
BioCentury | Jun 11, 2012
Clinical News

Endometrial Regenerative Cells: Phase II ongoing

...have no other treatment options. ERCell has exclusive rights to ERC from Medistem in Russia. ERCell LLC...
BioCentury | Mar 12, 2012
Company News

ERCell, Medistem deal

...can be used for regulatory approval in Russia and the U.S. Terms were not disclosed. ERCell...
...cells, which are in Phase II testing to treat heart failure, from Medistem in Russia. ERCell LLC...
BioCentury | Feb 27, 2012
Company News

Medistem, Shanghai Jia Fu Medical Apparatus Inc. deal

...dose-escalation Phase I trial evaluating ERC in CLI patients. Earlier this year, Medistem and partner ERCell LLC...
BioCentury | Feb 13, 2012
Clinical News

Endometrial Regenerative Cells: Phase II started

...Medistem and partner ERCell began the double-blind Phase II RECOVER-ERC trial to evaluate 50 million, 100...
...have no other treatment options. ERCell has exclusive rights to ERC from Medistem in Russia. ERCell LLC...
Items per page:
1 - 6 of 6
BioCentury | Apr 1, 2013
Clinical News

Endometrial Regenerative Cells: Preliminary Phase II data

...the Journal of Translational Medicine. ERCell has exclusive rights to ERCs from Medistem in Russia. ERCell LLC...
BioCentury | Jul 23, 2012
Clinical News

Endometrial Regenerative Cells: Phase I/II started

...50 million, 100 million and 200 million intramuscular ERC in about 15 patients with CLI. ERCell...
...Chinese market. Medistem and Jia Fu are initially focusing on CLI (see BioCentury, Feb. 27). ERCell LLC...
BioCentury | Jun 11, 2012
Clinical News

Endometrial Regenerative Cells: Phase II ongoing

...have no other treatment options. ERCell has exclusive rights to ERC from Medistem in Russia. ERCell LLC...
BioCentury | Mar 12, 2012
Company News

ERCell, Medistem deal

...can be used for regulatory approval in Russia and the U.S. Terms were not disclosed. ERCell...
...cells, which are in Phase II testing to treat heart failure, from Medistem in Russia. ERCell LLC...
BioCentury | Feb 27, 2012
Company News

Medistem, Shanghai Jia Fu Medical Apparatus Inc. deal

...dose-escalation Phase I trial evaluating ERC in CLI patients. Earlier this year, Medistem and partner ERCell LLC...
BioCentury | Feb 13, 2012
Clinical News

Endometrial Regenerative Cells: Phase II started

...Medistem and partner ERCell began the double-blind Phase II RECOVER-ERC trial to evaluate 50 million, 100...
...have no other treatment options. ERCell has exclusive rights to ERC from Medistem in Russia. ERCell LLC...
Items per page:
1 - 6 of 6